Under the terms of the SOW, P3 will receive management services fees for the performance years 2026 and 2027. Starting from 2028, the financial relationship will transition to a global risk agreement, indicating a shift towards a more integrated financial model that aligns incentives between P3 and the Client. The MSA is set to run until December 31, 2030, with automatic renewals unless terminated by either party with appropriate notice.
The agreement includes provisions for performance metrics, allowing the Client to terminate the SOW if P3 fails to meet specific performance targets for the 2026 performance year. Additionally, if the Client decides not to pursue a Medicare Advantage plan bid for 2027-2028, the SOW will terminate automatically, with P3 entitled to a breakup fee based on its incurred costs. This structure is designed to ensure accountability and performance alignment between the parties.
This development is expected to positively impact P3 Health Partners' operational execution and strategic outlook, as it solidifies their role in the Medicare Advantage space and enhances their service offerings. The agreement reflects P3's commitment to improving healthcare delivery through innovative support models, which could lead to increased market share and revenue growth in the coming years.
